Drug Trial Radar · NCT02572323
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Feb 15, 2017
Primary completion
Oct 15, 2023
Study completion Oct 15, 2023
Sponsor
- Lead sponsor
- University of California, San DiegoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Southern California; PalmTree Clinical Research Inc.; University of California, San Francisco
- First posted
- Oct 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
Conditions
- Mild Cognitive Impairment
Interventions
TesamorelinDrug
Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Neurocognitive PerformanceTime frame: Baseline and week 24
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Keck School of Medicine of the University of Southern California
Los Angeles, California
PalmTree
Palm Springs, California
HIV Neurobehavioral Research Program (HNRP)
San Diego, California
University of California, San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.